Enrollment in This Study Is Complete
Investigational Study to Assess the Performance of the AlphaVac F1885 System in the Treatment of Pulmonary Embolism (PE)
APEX-AV by AngioDynamics was a prospective, single-arm, multi-center Investigational Device Exemption (IDE) study that evaluated the safety and effectiveness of the AV F1885 Multipurpose Aspiration (MMA) System for the treatment of acute pulmonary embolism
The AlphaVac F1885 System is indicated for the non-surgical removal of thrombi or emboli from the vasculature, as well as the aspiration of contrast media and other fluids from the vasculature.
The AlphaVac Cannula is intended for use in the venous system and for the treatment of pulmonary embolism.
The AlphaVac Handle is indicated as a vacuum source for the AlphaVac MMA System.
Percutaneous mechanical thrombectomy may reduce the need for thrombolytic therapy, which may reduce the length of ICU stay.1,2
The AlphaVac F1885 System has been cleared for the treatment of pulmonary embolism.
1. Karthikesalingam A, Young E L, Hinchliffe R J, Loftus I M, Thompson M M, Holt P J E,A Systematic Review of Percutaneous Mechanical Thrombectomy in the Treatment of Deep Venous Thrombosis. EJVES, 2011; 41(4): 554-565.
2. Muli Jogi RK, Damodharan K, Leong HL, et al. Catheter-directed thrombolysis versus percutaneous mechanical thrombectomy in the management of acute limb ischemia: a single center review. CVIR Endovasc. 2018;1(1):35.
AngioDynamics, and the AngioDynamics logo, AlphaVac, and the AlphaVac are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate or a subsidiary. © 2024 AngioDynamics, Inc.